- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Diffuse large B-cell lymphoma (DLBCL)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Loncastuximab Tesirine – March 2026
Powder for I.V. infusion 10 mg,
Last updated
11 March 2026